NASDAQ:AMGN

Amgen Stock Forecast, Price & News

Most-Downgraded Stocks

$258.60

+1.50 (+0.58 %)

(As of 01/26/2021 04:48 PM ET)

Add

Compare

Today's Range

$254.86

Now: $258.60▼

$259.07

50-Day Range

$220.99

MA: $233.69▼

$253.50

52-Week Range

$177.05

Now: $258.60▼

$264.97

Volume2.01 million shs

Average Volume2.41 million shs

Market Capitalization$150.55 billion

P/E Ratio20.85

Dividend Yield2.49%

Beta0.76

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company, as well as has a strategic agreement with McKesson Corporation to help improve cancer care in community oncology settings. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

MarketRank^™

Overall MarketRank^™

2.26 out of 5 stars

Medical Sector

18th out of 1,925 stocks

Biological Products, Except Diagnostic Industry

2nd out of 177 stocks

2.3 Analyst's Opinion

Consensus Rating
Amgen has received a consensus rating of Buy. The company's average rating score is 2.54, and is based on 16 buy ratings, 11 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $255.08, Amgen has a forecasted downside of 1.1% from its current price of $258.00.
Amount of Analyst Coverage
Amgen has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0 Community Rank

Outperform Votes
Amgen has received 1,429 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Amgen has received 955 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Amgen has received 59.94% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote “Outperform” if you believe AMGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Yield
Amgen pays a meaningful dividend of 2.52%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Amgen has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Amgen is 43.18%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Amgen will have a dividend payout ratio of 37.65% next year. This indicates that Amgen will be able to sustain or increase its dividend.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $296,590.00 in company stock.
Percentage Held by Insiders
Only 0.36% of the stock of Amgen is held by insiders.
Percentage Held by Institutions
75.23% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Amgen are expected to grow by 5.26% in the coming year, from $16.15 to $17.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amgen is 20.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.13.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amgen is 20.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 37.05.
Price to Earnings Growth Ratio
Amgen has a PEG Ratio of 1.90. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Amgen has a P/B Ratio of 15.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:AMGN

Previous Symbol

CUSIP03116210

CIK318154

Webwww.amgen.com

Phone805-447-1000

Employees23,400

Year FoundedN/A

Debt

Debt-to-Equity Ratio3.12

Current Ratio2.28

Quick Ratio1.88

Price-To-Earnings

Trailing P/E Ratio20.85

Forward P/E Ratio16.01

P/E Growth1.9

Sales & Book Value

Annual Sales$23.36 billion

Price / Sales6.44

Cash Flow$19.92 per share

Price / Cash Flow12.98

Book Value$16.28 per share

Price / Book15.88

Profitability

EPS (Most Recent Fiscal Year)$14.82

Net Income$7.84 billion

Net Margins29.42%

Return on Equity95.55%

Return on Assets15.52%

Miscellaneous

Outstanding Shares582,169,000

Market Cap$150.55 billion

Next Earnings Date2/2/2021 (Confirmed)

OptionableOptionable

$258.60

+1.50 (+0.58 %)

(As of 01/26/2021 04:48 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Amgen (NASDAQ:AMGN) Frequently Asked Questions

How has Amgen's stock price been impacted by Coronavirus?

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMGN shares have increased by 29.8% and is now trading at $257.93.
View which stocks have been most impacted by COVID-19.

Is Amgen a buy right now?

28 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 1 sell rating, 11 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amgen stock.
View analyst ratings for Amgen or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Amgen?

Wall Street analysts have given Amgen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amgen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Robert A. Bradway's approval rating as Amgen's CEO?

806 employees have rated Amgen CEO Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among Amgen's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for Amgen.

How can I listen to Amgen's earnings call?

Amgen will be holding an earnings conference call on Tuesday, February 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) posted its quarterly earnings results on Monday, November, 2nd. The medical research company reported $4.37 EPS for the quarter, topping the Zacks' consensus estimate of $3.75 by $0.62. The medical research company earned $6.42 billion during the quarter, compared to analyst estimates of $6.38 billion. Amgen had a net margin of 29.42% and a trailing twelve-month return on equity of 95.55%.
View Amgen's earnings history.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Wednesday, December 16th. Stockholders of record on Monday, February 15th will be given a dividend of $1.76 per share on Monday, March 8th. This represents a $7.04 dividend on an annualized basis and a yield of 2.73%. The ex-dividend date of this dividend is Thursday, February 11th. This is a positive change from Amgen's previous quarterly dividend of $1.60.
View Amgen's dividend history.

Is Amgen a good dividend stock?

Amgen pays an annual dividend of $6.40 per share and currently has a dividend yield of 2.52%. Amgen does not yet have a strock track record of dividend growth. The dividend payout ratio of Amgen is 43.18%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Amgen will have a dividend payout ratio of 37.65% next year. This indicates that Amgen will be able to sustain or increase its dividend.
View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY20 earnings guidance on Wednesday, October, 28th. The company provided earnings per share (EPS) guidance of $15.80-16.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.78. The company issued revenue guidance of $25.1-25.5 billion, compared to the consensus revenue estimate of $25.39 billion.

What price target have analysts set for AMGN?

28 brokerages have issued 1 year price targets for Amgen's stock. Their forecasts range from $185.00 to $304.00. On average, they expect Amgen's share price to reach $255.08 in the next twelve months. This suggests that the stock has a possible downside of 1.1%.
View analysts' price targets for Amgen or view Wall Street analyst' top-rated stocks.

Who are some of Amgen's key competitors?

Some companies that are related to Amgen include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Novavax (NVAX) and United Therapeutics (UTHR).
View all of AMGN's competitors.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), The Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and The Home Depot (HD).

Who are Amgen's key executives?

Amgen's management team includes the following people:

Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 57, Pay $5.61M)
Mr. Jonathan P. Graham, Exec. VP, Gen. Counsel & Sec. (Age 59, Pay $2.44M)
Dr. David M. Reese M.D., Exec. VP of R&D (Age 57, Pay $2.54M)
Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 53, Pay $2.66M)
Mr. Peter H. Griffith, Exec. VP & CFO (Age 61)
Mr. Esteban Santos, Exec. VP of Operations (Age 52)
Ms. Linda H. Louie, VP of Fin. & Chief Accounting Officer
Mr. Mike Zahigian, Sr. VP & Chief Information Officer
Mr. Arvind Sood, VP of Investor Relations
Nancy A. Grygiel, Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.23%), Sarasin & Partners LLP (0.18%), New York State Teachers Retirement System (0.14%), Bartlett & Co. LLC (0.07%), Nisa Investment Advisors LLC (0.06%) and Capital Wealth Planning LLC (0.05%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams and Ronald D Sugar.
View institutional ownership trends for Amgen.

Which major investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including RNC Capital Management LLC, TIAA FSB, New York State Teachers Retirement System, British Airways Pensions Investment Management Ltd, Pacer Advisors Inc., Strs Ohio, Highland Capital Management LLC, and State of Alaska Department of Revenue. Company insiders that have sold Amgen company stock in the last year include David Piacquad, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen or view top insider-selling stocks.

Which major investors are buying Amgen stock?

AMGN stock was acquired by a variety of institutional investors in the last quarter, including Sarasin & Partners LLP, Candriam Luxembourg S.C.A., Capital Wealth Planning LLC, Crossmark Global Holdings Inc., Chesley Taft & Associates LLC, Louisiana State Employees Retirement System, Janney Montgomery Scott LLC, and Oak Harvest Investment Services.
View insider buying and selling activity for Amgen or or view top insider-buying stocks.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $257.93.

How big of a company is Amgen?

Amgen has a market capitalization of $150.16 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

What is Amgen's official website?

The official website for Amgen is www.amgen.com.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here